Organon & (OGN)

What Could Go Wrong

1. 01Secular decline in mature pharmaceutical portfolio as patents expire and generic competition intensifies, with limited pipeline to offset erosion (minimal R&D investment model)
2. 02Regulatory pricing pressure globally, particularly in US (IRA negotiations for Medicare), Europe (reference pricing), and emerging markets (government price controls)
3. 03Biosimilar market commoditization as multiple competitors enter (adalimumab market now has 10+ biosimilars, compressing margins)
4. 04Women's health market disruption from long-acting reversible contraceptive generics and telehealth prescription models
5. 05Large pharma competitors (Pfizer, Novartis, Teva) with greater scale in biosimilars and established brands, able to sustain price competition
6. 06Specialty women's health companies (CooperSurgical, Ferring) with focused R&D pipelines potentially displacing Organon's aging franchises
7. 07Generic manufacturers (Sandoz, Mylan/Viatris) aggressively pricing established products, accelerating revenue erosion
8. 08High leverage (estimated $8-9B debt, 5-6x net debt/EBITDA) limits financial flexibility and requires sustained free cash flow generation for deleveraging

OGN Chart

My Notes

• value - The stock trades at distressed multiples (0.3x P/S, 1.2x EV/EBITDA) reflecting structural decline concerns and high leverage…
• Rising interest rates increase debt service costs on the company's $8-9B debt load (estimated 60-70% floating rate exposure)…
• Watch on earnings: Biosimilar revenue run-rate and quarterly sequential growth (Hadlima, Renflexis market share data), Women's health franchise organic growth rate (constant currency, volume vs price mix), Net debt/EBITDA leverage ratio and quarterly debt paydown progress.